Dsm Capital Partners Llc increased its stake in Zoetis (ZTS) by 18.65% based on its latest 2016Q3 regulatory filing with the SEC. Dsm Capital Partners Llc bought 634,328 shares as the company’s stock rose 9.61% with the market. The hedge fund held 4.04 million shares of the major pharmaceuticals company at the end of 2016Q3, valued at $209.86M, up from 3.40 million at the end of the previous reported quarter. Dsm Capital Partners Llc who had been investing in Zoetis for a number of months, seems to be bullish on the $26.32B market cap company. The stock is down 1.13% or $0.61 hitting $53.32, despite the positive news. About 2.70 million shares traded hands. Zoetis Inc (NYSE:ZTS) has risen 11.54% since June 7, 2016 and is uptrending. It has outperformed by 4.12% the S&P500.
Dsm Capital Partners Llc, which manages about $5.78B and $6.20B US Long portfolio, decreased its stake in Celgene (NASDAQ:CELG) by 41,787 shares to 1.87 million shares, valued at $195.36 million in 2016Q3, according to the filing. It also reduced its holding in Alexion Pharmaceuticals (NASDAQ:ALXN) by 144,802 shares in the quarter, leaving it with 1.17 million shares, and cut its stake in Newell Brands (NYSE:NWL).
Dsm Capital Partners Llc is a New York-based hedge fund with more than $5.78 billion AUM in November, 2014. Taken from Dsm Capital Partners latest Adv, the fund reported to have 24 full and part-time employees. Among which 12 performing investment advisory and research functions. The hedge fund had more than 1700 clients.
Insitutional Activity: The institutional sentiment increased to 1.19 in 2016 Q3. Its up 0.11, from 1.08 in 2016Q2. The ratio improved, as 37 funds sold all ZTS shares owned while 206 reduced positions. 70 funds bought stakes while 218 increased positions. They now own 446.74 million shares or 1.13% less from 451.82 million shares in 2016Q2. Glg Ptnrs Lp has 54,000 shares for 0.09% of their US portfolio. Ironwood Invest Mgmt Ltd Liability Company holds 0.27% or 6,851 shares in its portfolio. Natixis Asset Management has invested 0.01% of its portfolio in Zoetis Inc (NYSE:ZTS). Highland Cap Mngmt Ltd Liability Company holds 36,959 shares or 0.16% of its portfolio. Commonwealth Financial Bank Of holds 0% of its portfolio in Zoetis Inc (NYSE:ZTS) for 6,858 shares. Mutual Of America Mngmt Ltd Company has 66,391 shares for 0.07% of their US portfolio. The Georgia-based Suntrust Banks has invested 0.02% in Zoetis Inc (NYSE:ZTS). Allsquare Wealth Lc last reported 597 shares in the company. West Family Invests Inc owns 21,174 shares or 0.2% of their US portfolio. Pittenger Anderson has 55,930 shares for 0.32% of their US portfolio. Congress Asset Mngmt Ma last reported 274,723 shares in the company. Mizuho Asset Management Coltd accumulated 4,916 shares or 0.06% of the stock. Profund Ltd, a Maryland-based fund reported 31,259 shares. Everett Harris & Ca holds 0.01% of its portfolio in Zoetis Inc (NYSE:ZTS) for 4,606 shares. Aperio Gp holds 177,940 shares or 0.07% of its portfolio.
Insider Transactions: Since September 1, 2016, the stock had 1 insider buy, and 4 insider sales for $3.24 million net activity. $102,680 worth of Zoetis Inc (NYSE:ZTS) shares were bought by MCCALLISTER MICHAEL B. 32,097 Zoetis Inc (NYSE:ZTS) shares with value of $1.64 million were sold by Chen Heidi C.. $500,059 worth of Zoetis Inc (NYSE:ZTS) was sold by PECK KRISTIN C. Another trade for 9,797 shares valued at $494,063 was made by Lagano Roxanne on Tuesday, November 8. $710,838 worth of Zoetis Inc (NYSE:ZTS) was sold by Fenton Andrew.
Another recent and important Zoetis Inc (NYSE:ZTS) news was published by Streetinsider.com which published an article titled: “Deutsche Bank Starts Zoetis Inc. (ZTS) at Buy” on December 20, 2016.
According to Zacks Investment Research, “Zoetis discovers, develops, manufactures and markets veterinary vaccines and medicines, complemented by diagnostic products and genetic tests and supported by a range of services.”
Zoetis Inc (NYSE:ZTS) Ratings Coverage
Out of 14 analysts covering Zoetis Inc (NYSE:ZTS), 11 rate it a “Buy”, 1 “Sell”, while 2 “Hold”. This means 79% are positive. Zoetis Inc has been the topic of 24 analyst reports since July 24, 2015 according to StockzIntelligence Inc. The stock has “Hold” rating given by Zacks on Monday, September 7. On Thursday, February 4 the stock rating was initiated by Credit Suisse with “Outperform”. Zacks upgraded the shares of ZTS in a report on Thursday, September 17 to “Buy” rating. Citigroup maintained the stock with “Neutral” rating in Thursday, August 4 report. William Blair upgraded the shares of ZTS in a report on Thursday, August 6 to “Outperform” rating. The firm has “Overweight” rating given on Thursday, December 15 by PiperJaffray. BMO Capital Markets upgraded the stock to “Outperform” rating in Friday, September 11 report. Jefferies maintained Zoetis Inc (NYSE:ZTS) on Tuesday, June 14 with “Buy” rating. Goldman Sachs downgraded the shares of ZTS in a report on Friday, May 6 to “Sell” rating. The stock has “Buy” rating given by Stifel Nicolaus on Wednesday, June 1.
ZTS Company Profile
Zoetis Inc., incorporated on July 25, 2012, is engaged in the discovery, development, manufacture and commercialization of animal health medicines and vaccines, with a focus on both livestock and companion animals. The Firm has a diversified business, marketing products across over eight core species: cattle, swine, poultry, sheep and fish (collectively, livestock), and dogs, cats and horses (collectively, companion animals), and within over five product categories: anti-infectives, vaccines, parasiticides, medicated feed additives and other pharmaceuticals. The Firm operates through two divisions: the United States and International. Within each of these divisions, the Company offers a diversified product portfolio for both livestock and companion animal customers. In addition, its Client Supply Services (CSS) organization provides contract manufacturing services to third parties.
Receive News & Ratings Via Email - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings with our FREE daily email newsletter.